Protalix BioTherapeutics, Inc.: Revision history

20 August 2022

• curprev 14:1014:10, 20 August 2022 95.149.241.133 talk 1,145 bytes +11 No edit summary undo

13 August 2022

• curprev 21:2221:22, 13 August 2022 109.180.50.163 talk 1,134 bytes +15 No edit summary undo

30 July 2022

• curprev 20:2120:21, 30 July 2022 172.18.0.2 talk 1,119 bytes +1,119 Created page with "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the las..."